<DOC>
	<DOCNO>NCT01320085</DOCNO>
	<brief_summary>The study assess safety efficacy single-agent MEK162 adult patient locally advance unresectable metastatic malignant cutaneous melanoma , harbor BRAFV600E NRAS mutation .</brief_summary>
	<brief_title>A Phase II Study Single Agent MEK162 Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Locally advanced metastatic cutaneous melanoma AJCC Stage IIIB IV , potentially curable surgery BRAF NRAS mutation tumor tissue All patient enrol provide sufficient fresh archival tumor sample baseline enable confirmation BRAF NRAS mutation additional analysis describe protocol Evidence measurable tumor disease per RECIST WHO performance status 02 Adequate organ function laboratory parameter History evidence central serous retinopathy ( CSR ) , retinal vein occlusion ( RVO ) eye condition would consider risk factor CSR RVO Patients unstable CNS metastasis Prior treatment MEK inhibitor Impaired cardiovascular function HIV , active Hepatitis B , and/or active Hepatitis C infection Pregnant nursing ( lactate ) woman Women childbearing potential UNLESS comply protocol contraceptive requirement Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic melanoma ,</keyword>
	<keyword>BRAF-mutant ,</keyword>
	<keyword>NRAS-mutant</keyword>
</DOC>